Includes: 1. New Grant for SPO # is 46480 for a new NIH stimulation bill grant # 1RC2DE020771-01 PI: Longaker Title: Calvarial Regeneration using Biomatrix-Encapsulated Skeletal Progenitors; ----2. New Grant for SPO: 41258 grant # 3R21DE019274-02S1. PI: Longaker Title: The Enhanced Calvarial Regeneration Via RNAi-Mediated Suppression of BMP Antagonism The funding section of the eprotocol application has also been updated; -----Personnel Updates.
The expiration date of this approval is 03/09/2010 at Midnight. If this project is to continue beyond that date, you must submit an updated protocol in advance for the IRBs re-approval. If this protocol is used in conjunction with any other human use it must be re-approved. Proposed changes to approved research must be reviewed and approved prospectively by the IRB. No changes may be initiated without prior approval by the IRB, except where necessary to eliminate apparent immediate hazards to subjects. (Any such exceptions must be reported to the IRB within 10 working days.) Unanticipated problems involving risks to participants or others and other events or information, as defined and listed in the Report Form, must be submitted promptly to the IRB. (See Events and Information that Require Prompt Reporting to the IRB at http://humansubjects.stanford.edu.)
All continuing projects and activities must be reviewed and re-approved on or before Midnight of the expiration date. The approval period will be less than one year if so determined by the IRB. It is your responsibility to resubmit the project to the IRB for continuing review and to report the completion of the protocol to the IRB within 30 days.
Please remember that all data, including all signed consent form documents, must be retained for a minimum of three years past the completion of this research. Additional requirements may be imposed by your funding agency, your department, or other entities. (See Policy on Retention of and Access to Research Data at http://stanford.edu/dept/DoR/rph/2-10.html.)
This institution is in compliance with requirements for protection of human subjects, including 45 CFR 46, 21 CFR 50 and 56, and 38 CFR 16. The IRB approved human subjects involvement in your research project on 09/25/2009. Prior to subject recruitment and enrollment, if this is: a Cancer-related study, you must obtain Cancer Center Scientific Review Committee (SRC) approval; a GCRC study, you must obtain GCRC approval; a VA study, you must obtain VA RD Committee approval; and if a contract is involved, it must be signed. All continuing projects and activities must be reviewed and re-approved on or before Midnight of the expiration date.
Certification of Human Subjects Approvals
The approval period will be less than one year if so determined by the IRB. It is your responsibility to resubmit the project to the IRB for continuing review and to report the completion of the protocol to the IRB within 30 days.
This institution is in compliance with requirements for protection of human subjects, including 45 CFR 46, 21 CFR 50 and 56, and 38 CFR 16. The expiration date of this approval is 03/09/2010 at Midnight. If this project is to continue beyond that date, you must submit an updated protocol in advance for the IRBs re-approval. If this protocol is used in conjunction with any other human use it must be re-approved. Proposed changes to approved research must be reviewed and approved prospectively by the IRB. No changes may be initiated without prior approval by the IRB, except where necessary to eliminate apparent immediate hazards to subjects. (Any such exceptions must be reported to the IRB within 10 working days.) Unanticipated problems involving risks to participants or others and other events or information, as defined and listed in the Report Form, must be submitted promptly to the IRB. (See Events and Information that Require Prompt Reporting to the IRB at http://humansubjects.stanford.edu.)
This institution is in compliance with requirements for protection of human subjects, including 45 CFR 46, 21 CFR 50 and 56, and 38 CFR 16. 

